Introduction:

Mucopolysaccharidosis (MPS) is a rare gene-mutation disorder that is inheritable. It’s caused by the body’s inability to properly carry out enzymic actions in Lysosome of the cells. In this blog, we will take a detailed look at MPS, its causes, different types, symptoms, diagnosis, treatment, and ongoing research efforts. Whether you’re a patient, a caregiver, or simply curious about rare genetic diseases, this guide will provide a comprehensive overview.

Understanding Mucopolysaccharidosis (MPS):

Mucopolysaccharidosis is a metabolism related condition that affects how the body processes molecules essential for the development and maintenance of the body, where the chromosome linked mutation effects the IDS gene. This mutation causes disturbance in the normal and proper functioning of a Lysosomal enzyme (one or more of the 11 present) leading to build-up/accumulation of Glycosaminoglycans (GAGs) in areas of body such as the Brain, Blood and connective tissues. This build-up then leads to a Progressive and permanent damage to the cells hence, resulting in Phenotypical, Musculo-Skelton and Neurological morbidities.

Glycosaminoglycans (GAGs) are typically broken down by enzymes in the lysosomes, but in Mucopolysaccharidosis (MPS), a deficiency of these enzymes causes Glycosaminoglycans (GAGs) to accumulate leading to the above-mentioned events

Causes of Mucopolysaccharidosis (MPS):

Mucopolysaccharidosis (MPS) is caused by mutations in IDS gene that are responsible for producing enzymes involved in the breakdown of Glycosaminoglycans (GAGs). Occurrence of MPS causes a deficiency or inability of the Lysosomal enzymes (one or many of the eleven present) in helping of breaking down of Glycosaminoglycans (GAGs).  Mucopolysaccharidosis (MPS) is an inheritable disorder that can be passed down by either if not both the parents.

Genetic diseases happen when there are changes in the genes that produce specific enzymes, which are passed down from both parents. If a person inherits one faulty gene from each parent for the same condition, they can develop what’s called a recessive genetic disorder. This means the disorder only shows up when both copies of the gene from both parents are abnormal and inherited fully. If someone only inherits only one faulty gene from either of the parents, they won’t usually show symptoms but can still pass it on to their children i.e., they become carriers for the disease. All types of Mucopolysaccharidosis (MPS) are autosomal recessive trait linked except for the Type 2 Mucopolysaccharidosis called Hunters Syndrome which is related to X-chromosome mutation, which means it predominantly occurs in men whilst women become the carriers.

Types of Mucopolysaccharidosis (MPS)

Mucopolysaccharidosis (MPS) is classified into various types depending on the deficiency of the specific Lysosomal enzyme; they include the following types:

1. Mucopolysaccharidosis (MPS) I (Hurler Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome): Mucopolysaccharidosis (MPS) I is further divided into three classes based on severity; they include Hurler MPS, Hurler-Scheie MPS and Scheie MPS (Most severe, moderately severe and mild respectively). This type of MPS is caused by a deficiency in an enzyme called Alpha-L-Iduronidase (Lysosomal enzyme). Depending on, the type of Mucopolysaccharidosis (MPS) 1, a delay or cease in the development is seen. In case of Hurlers Syndrome mental development stops between age of 1 and 5 with increase of symptoms including development of short stature, multiple skeletal abnormalities, Hernias, Distinct Facial features, and Enlarged organs (Spleen and Liver). Eventually leading to mortality by the age of 10.

2. Mucopolysaccharidosis (MPS) II (Hunter Syndrome): This is a X-linked Mucopolysaccharidosis (MPS) caused by a deficiency in the Iduronate-2-Sulfatase enzyme (Lysosomal enzyme). It primarily affects males (due to presence of only one X chromosome) and ranges from mild to severe. Developmental issues start between age of 2 and 4 showing symptoms such as Coarse facial features, Joint stiffness, Hydrocephalus and Hepato-Spleen Magaly. In severe cases the end result is often a Cardiovascular failure by the age of 15 but in lesser severe cases the developmental issues develop after the passing of age of 10 and such cases survive up to a good age of 50 years with milder symptoms.

3. Mucopolysaccharidosis (MPS) III (Sanfilippo Syndrome): It is further divided into four types (A, B, C and D) and involves a deficiency in one of four enzymes that help break down Heparan Sulfate, leading to severe Neurodegeneration. Type A is considered to be the most severe type of the four. The symptoms include Behavioural changes, Sleep-related changes and cognitive changes which often lead to Vision and hearing loss over time. Overtime progression leads to complete or partial caseation of Musculo-skeleton movement. Life Expectancy varies widely where some cases witness succumbing int their childhood whereas others live up to age of 20’s and 30’s.

4. Mucopolysaccharidosis (MPS) IV (Morquio Syndrome): It has two types:

Type A: This happens when the body doesn’t have enough of an enzyme called N-AcetylGalactosamine-6-Sulfatase, which helps break down a sugar called Chondroitin-6-Sulfate.

Type B: In this type, the body is missing or low on the enzyme Beta-Galactosidase, which is needed to break down another sugar called Keratan Sulfate.

Symptoms include Loss of hearing and Vision and Skeletal dysplasia (including odontoid hypoplasia, protruded sternum, a curved spine, knock-knees and etc). Onset is seen after the age of 3 with life expectancy not preceding more than 20’s (in less severe cases)

5. Mucopolysaccharidosis (MPS) VI (Maroteaux-Lamy Syndrome): This type of MPS is caused by a deficiency in Arylsulfatase B. It has various symptoms varying over a large area with mental development typically being unaffected People with MPS VI experience normal growth at first but growth stops suddenly around age 8. Skeletal changes get worse over time leading to limited or ceased mobility. Many physical symptoms resemble symptoms of Type I MPS with thickening of the dura’s, loss of hearing and vision, Hepato-Spleen Magaly, Cardiovascular issues and breathing symptoms. Life expectancy depends on disease severity and is typically around 20-30 years of age.

6. Mucopolysaccharidosis (MPS) VII (Sly Syndrome): This rare form of MPS resulting from a deficiency of Beta-Glucuronidase affecting multiple organ systems. Symptoms include mild to moderate intellectual disability, Hydrocephalus, Cardiovascular disease, Vision Loss, Carpal Tunnel Syndrome, Skeletal problems (including joint stiffness and short stature). In addition to skeletal problems, some children may have Pneumonia during their first years of life. Life expectancy of about age of 20’s is seen in milder cases with severe cases causing mortality in first few months of life.

7. Mucopolysaccharidosis (MPS) IX (Natowicz syndrome): This is an extremely rare type of MPS caused by the lack of an enzyme called Hyaluronidase. People with MPS IX usually don’t have problems with joint movement or learning abilities. The main symptoms include soft lump like formations around the joints that can become swollen and painful. Other signs of the condition may include mild changes in Facial appearance, being shorter than average, frequent ear infections, and some bone weakening, which can be confirmed through scans. Each type presents its own unique challenges, and while there is no cure, early diagnosis and management can improve quality of life and help in prolongment of life expectancy.

Symptoms of Mucopolysaccharidosis (MPS)

Symptoms of Mucopolysaccharidosis (MPS) vary depending on the type of MPS and its severity. However, some common features include:

• Skeletal abnormalities such as short stature, joint stiffness and skeletal deformities
• Enlarged organs including liver and spleen
• Hearing loss and vision problems
• Cardiovascular and respiratory issues
• Developmental delay and Intellectual disability, especially in more severe forms
• Facial and physical dysmorphia

Symptoms usually appear early in childhood and worsen as Glycosaminoglycans (GAGs) accumulate in tissues over time. Because of the progressive nature of the disease, early intervention is crucial.

Diagnosis of Mucopolysaccharidosis (MPS)

Although, Mucopolysaccharidosis (MPS) is an untreatable disorder its early detection can help in preventing damage to a certain extent and help in improving quality of life and proper managing of the disease. Diagnosing MPS includes a clinical examination for the presence of characteristic symptoms and Laboratory tests, including enzyme assays and genetic testing to confirm the diagnosis. Urine tests may reveal elevated levels of Glycosaminoglycans (GAGs) which are the main cause of MPS.

Treatment Options for Mucopolysaccharidosis (MPS)

While there is no cure for Mucopolysaccharidosis (MPS), various treatments aim to manage symptoms, improve quality of life, and slow disease progression. This is achieved by:

• Enzyme Replacement Therapy (ERT):

 In certain types of Mucopolysaccharidosis (MPS) where enzyme related deficiency is seen including MPS I, II, and VI, Enzyme replacement Therapy can be used to replace the deficient enzyme through an intravenous infusion. It helps reduce the build-up of Glycosaminoglycans (GAGs) in the body, helping in managing pain and non-Neurological symptoms.

Enzymes do not cross the Blood-Brain-barrier (BBB) hence, ERT doesn’t help with Vision and Nervous related issues

• Hematopoietic Stem Cell Transplantation (HSCT):

This treatment involves replacing the patient’s defective stem cells with healthy ones from a donor through Bone Marrow transplant or Umbilical Cord Stem Cell Transplant.

This is most effective when performed early in life and has been used primarily in MPS type I.

• Surgical Interventions:

 Patients with Skeleton and Cardiovascular symptoms can be referred surgeries to treat the morbidities. Corneal transplants can be done in patients who have a vision loss and Surgeries to help improve beathing quality can be performed

• Supportive Therapies:

Physical therapy, occupational therapy, and respiratory therapy help manage symptoms and maintain mobility.

Use of Physician prescribed drugs can help improve Symptoms and manage the disease.

Each treatment option has its own set of risks and benefits, and the right approach depends on the specific type of Mucopolysaccharidosis (MPS) and the individual patient’s needs.

Current Research and Future Directions:

Research into Mucopolysaccharidosis (MPS) is ongoing, with several promising areas under investigation, including:

-Gene Therapy: This area of research focuses on exploring how to replace or repair defective genes responsible for enzyme deficiencies Mucopolysaccharidosis (MPS). Early trials have shown potential, but this area of research is still in its trails and is not recommended for clinical practice or trails.

-Substrate Reduction Therapy (SRT): This treatment aims to reduce the production of Glycosaminoglycans (GAGs), limiting their accumulation. It could be used alongside existing therapies to improve patient outcomes.

– Small Molecule Therapy: Researchers are testing small molecules that may enhance enzyme function or cross the blood-brain barrier, potentially addressing the neurological symptoms of MPS. This is currently being studied in animal models.

– Mutation prevention Therapy: Mucopolysaccharidosis (MPS) is caused due to a mutation called Nonsense type Mutation. Currently research focuses on prevention of this type of mutation leading to prevention of MPS

Conclusion:

Mucopolysaccharidosis is a complex and challenging disorder with no promised cure but, new advances in diagnosis and treatment show an improvement in the lives of those affected. With continued research and early diagnosis and prevention, patients with Mucopolysaccharidosis (MPS) have better hopes to manage and live through MPS through enzyme replacement therapy, stem cell transplantation, or emerging treatments like gene therapy.

It’s important to seek comprehensive medical care and explore all available treatment options and opt for the best as requires by individual needs. With the right approach, patients can lead more comfortable and fulfilling lives despite the challenges posed by the disease.

*References* 

• https://www.ninds.nih.gov/health-information/disorders/mucopolysaccharidoses
• https://rarediseases.org/rare-diseases/mucopolysaccharidoses/
• https://medlineplus.gov/ency/article/001204.htm
• https://rarediseases.info.nih.gov/diseases/7065/mucopolysaccharidosis